Recursion Pharmaceuticals, Inc. (RXRX) Cash Flow Statement
Recursion Pharmaceuticals, Inc. (RXRX) generated -$350.5M of operating cash flow over the twelve months to 2026-06-30, spent $1.8M on capital expenditure and had free cash flow of -$352.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RXRXRecursion Pharmaceuticals, Inc.Follow RXRX — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.16 | -0.08 | -0.29 | -0.36 | -0.37 | -0.35 | |
| Capital expenditure | 0.04 | 0.04 | 0.01 | 0.01 | 0.01 | -0.00 | |
| Free cash flow | -0.20 | -0.12 | -0.30 | -0.37 | -0.38 | -0.35 | |
| Stock-based compensation | 0.01 | 0.03 | 0.05 | 0.08 | 0.11 | — |
USD billions · SEC XBRL
Recursion Pharmaceuticals, Inc. — questions
- What is Recursion Pharmaceuticals, Inc.'s operating cash flow?
- -$350.5M over the twelve months to 2026-06-30.
- How much does Recursion Pharmaceuticals, Inc. spend on capital expenditure?
- $1.8M over the twelve months to 2026-06-30.
- What is Recursion Pharmaceuticals, Inc.'s free cash flow?
- -$352.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Recursion Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.